[{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"792ef6e7-2868-41af-bc38-cd9bdc2aa080","acronym":"","url":"https://clinicaltrials.gov/study/NCT02317705","created_at":"2022-06-22T16:54:35.197Z","updated_at":"2024-07-02T16:36:08.532Z","phase":"Phase 2","brief_title":"Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer","source_id_and_acronym":"NCT02317705","lead_sponsor":"On Target Laboratories, LLC","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 positive"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2022-06-21"},{"id":"6ea69e56-9836-479f-95d8-b31e44da4f12","acronym":"FORWARD I","url":"https://clinicaltrials.gov/study/NCT02631876","created_at":"2021-01-18T12:47:56.060Z","updated_at":"2024-07-02T16:36:40.091Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","source_id_and_acronym":"NCT02631876 - FORWARD I","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 366","initiation":"Initiation: 03/02/2016","start_date":" 03/02/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-10-14"}]